Question to the Department of Health and Social Care:

To ask His Majesty's Government how many patients self-fund access to ruxolitinib to treat myelofibrosis, which is available privately but not on the NHS.

The National Institute for Health and Care Excellence (NICE) recommends ruxolitinib as an option for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis, also known as chronic idiopathic myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease. Ruxolitinib is available to National Health Service patients in line with NICE’s recommendations.

Information on the number of patients who self-fund ruxolitinib for myelofibrosis is not held centrally.